AdAlta completes enrolment for AD-214 fibrosis safety trial

–News Direct–

AdAlta Ltd (ASX:1AD) CEO Dr Tim Oldham tells Proactive the company has wrapped up the enrolment of healthy volunteers for its AD-214 Phase 1 extension study, and early indications are that it is well tolerated. The aim of the trial is to evaluate the safety of AD-214, the companys flagship candidate for treating fibrotic diseases including Idiopathic Pulmonary Fibrosis.

Oldham said: We are grateful to all the volunteers that have participated in this Phase 1 extension study.

The data being generated continues to show that AD-214 is well tolerated and is also helping to inform dosing regimens and the broader protocol for our coming Phase 2 study for AD-214.

Contact Details

Proactive Investors

Jonathan Jackson

+61 413 713 744

View source version on

AdAlta Ltd

comtex tracking


Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Daily Michigan News journalist was involved in the writing and production of this article.